Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of Cadonilimab (AK104) Combined With Chemotherapy in the Treatment of PD-1 Inhibitor Resistant Nasopharyngeal Carcinoma

NCT05790200 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

NCT NCT05790200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05790200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of Cadonilimab (AK104) Combined With Chemotherapy in the Treatment of PD-1 Inhibitor Resistant Nasopharyngeal Carcinoma
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2023
Completion date
September 22, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma